Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Epic-Bio
AddedFeb 17, 2024
UpdatedJun 18, 2026
Epic-Bio

Epic-Bio

Series A

Epic Bio: Pioneering the new era of gene expression modulation.

HQ
South San Francisco, CA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Epic Bio, founded with a mission to revolutionize genetic medicine, focuses on developing therapies that dynamically control gene expression to treat complex diseases. The company leverages the power of the epigenome, an overarching system in mammalian cells that regulates gene expression, to create innovative therapeutic solutions. Epic Bio aims to usher in a new era of gene regulation, offering advanced gene expression modulation systems that target a wide range of medical conditions.

Notable affiliated individuals and investors have significantly contributed to Epic Bio's growth and credibility in the biotech industry. The company's key achievements include pioneering advancements in epigenetic therapies and establishing a robust pipeline of potential treatments. Epic Bio's impact is marked by its commitment to transforming genetic medicine, providing hope for more effective treatments for complex diseases through precise gene regulation.

Epic-Bio - Similar Companies

Regel Therapeutics logo

Regel Therapeutics

EpiBiologics logo

EpiBiologics

epibiologics.com

Tune Therapeutics logo

Tune Therapeutics

tunetx.com

Epigentek Group logo

Epigentek Group

epigentek.com

EpiCypher logo

EpiCypher

epicypher.com

Chroma Medicine logo

Chroma Medicine

Epigenos Biosciences logo

Epigenos Biosciences

NewLimit logo

NewLimit

newlimit.com

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

GenEp logo

GenEp

genepbio.com

Encoded Therapeutics logo

Encoded Therapeutics

Amber Bio logo

Amber Bio

amber.bio

Empirico logo

Empirico

empiricotx.com

Algen Biotechnologies logo

Algen Biotechnologies

algenbio.com

GentiBio logo

GentiBio

gentibio.com

Epic-Bio - Quick Facts

Who are Epic-Bio's competitors?

Companies similar to Epic-Bio include Regel Therapeutics, EpiBiologics, Tune Therapeutics and Epigentek Group.

When was Epic-Bio founded?

Epic-Bio was founded in 2018.

Where is Epic-Bio's headquarters located?

Epic-Bio's headquarters is located in South San Francisco, CA, US.

When was Epic-Bio's last funding round?

Epic-Bio's most recent funding round was for $55M (USD) in July 2022.

How much has Epic-Bio raised to-date?

As of Jul 12, 2022, Epic-Bio has raised a total of $55M (USD).

How many employees does Epic-Bio have?

Epic-Bio has 35 employees as of Feb 4, 2024.

Epic-Bio - Classification

Ownership
  • Equity
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Gene Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software